Shandong Sinobioway Biomedicine Co Ltd (002581) — Cash Flow Quality Index

Latest as of September 2024: 0.05x

Shandong Sinobioway Biomedicine Co Ltd (002581) has a Cash Flow Quality Index of 0.05x as of September 2024. Operating cash flow of CN¥2.33 Million is below net income of CN¥44.24 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore 002581 operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.

Cash Flow Quality Index

0.05x
Operating CF / Net Income

Operating Cash Flow

CN¥2.33 Million
CNY

Net Income

CN¥44.24 Million
CNY

Data as of

Sep 2024
Most recent filing

Shandong Sinobioway Biomedicine Co Ltd Cash Flow Quality Index (2007–2021)

Historical Cash Flow Quality Index for Shandong Sinobioway Biomedicine Co Ltd across 13 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see how efficiently does Shandong Sinobioway Biomedicine Co Ltd generate cash.

Annual Cash Flow Quality Index for Shandong Sinobioway Biomedicine Co Ltd (2007–2021)

Year-by-year earnings quality comparison for Shandong Sinobioway Biomedicine Co Ltd.

Year Quality Index Operating CF (CNY) Net Income YoY Change
2021 -0.17x CN¥-46.02 Million CN¥278.69 Million ▼ -124.9%
2019 0.66x CN¥48.41 Million CN¥73.08 Million ▼ -4.2%
2017 0.69x CN¥271.11 Million CN¥392.20 Million ▲ +70.0%
2016 0.41x CN¥169.32 Million CN¥416.51 Million ▼ -29.1%
2015 0.57x CN¥137.73 Million CN¥240.30 Million ▼ -41.7%
2014 0.98x CN¥80.11 Million CN¥81.48 Million ▲ +4.1%
2013 0.94x CN¥83.13 Million CN¥88.04 Million ▲ +29.2%
2012 0.73x CN¥63.04 Million CN¥86.27 Million ▼ -34.2%
2011 1.11x CN¥74.43 Million CN¥66.98 Million ▼ -8.9%
2010 1.22x CN¥85.71 Million CN¥70.26 Million ▲ +32.8%
2009 0.92x CN¥54.06 Million CN¥58.82 Million ▼ -27.4%
2008 1.27x CN¥46.89 Million CN¥37.04 Million ▲ +64.8%
2007 0.77x CN¥25.07 Million CN¥32.63 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.